Ambrx Biopharma Inc
NYSE:AMAM
Ambrx Biopharma Inc
Revenue
Ambrx Biopharma Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Ambrx Biopharma Inc
NYSE:AMAM
|
Revenue
$7.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Ambrx Biopharma Inc
Revenue Breakdown
Breakdown by Geography
Ambrx Biopharma Inc
Breakdown by Segments
Ambrx Biopharma Inc
Total Revenue:
7.4m
USD
|
License Fees:
3.4m
USD
|
Research And Development Services:
2.1m
USD
|
Milestones:
1m
USD
|
Reimbursements:
820k
USD
|
See Also
What is Ambrx Biopharma Inc's Revenue?
Revenue
7.4m
USD
Based on the financial report for Dec 31, 2022, Ambrx Biopharma Inc's Revenue amounts to 7.4m USD.
What is Ambrx Biopharma Inc's Revenue growth rate?
Revenue CAGR 3Y
-10%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Ambrx Biopharma Inc have been -10% over the past three years .